Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients

Stroke

Volumn 45, Issue 8, 2014, Pages 2359-2365

  Chao, A Ching ^a,b   Liu, Ching Kuan ^a,b   Chen, Chih Hung ^c   Lin, Huey Juan ^d   Liu, Chung Hsiang ^e   Jeng, Jiann Shing ^f   Hu, Chaur Jong ^g   Chung, Chih Ping ^h   Hsu, Hung Yi ⁱ   Sheng, Wen Yung ^h   Hu, Han Hwa ^g  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cerebral hemorrhage; stroke

Indexed keywords

ALTEPLASE;

AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHINESE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANKIN SCALE; STROKE PATIENT; TREATMENT OUTCOME;

CEREBRAL HEMORRHAGE; STROKE;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84905961049     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005245     Document Type: Article

References (25)

1. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815.
2. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41:1984-1989.
3. Rha JH, Shrivastava VP, Wang Y, Lee KE, Ahmed N, Bluhmki E, et al. Thrombolysis for acute ischemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW) [published online ahead of print September 18, 2012]. Int J Stroke. doi: 10.1111/j.1747-4949.2012.00895.x. http://www.ncbi.nlm.nih.gov/pubm ed/?term=Rha+JH+and+Shrivastava+VP. Accessed June 2, 2014.
4. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
5. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010;41:885-890.
6. Yu CM, Chan TY, Tsoi WC, Sanderson JE. Heparin therapy in the Chinese-lower doses are required. QJM. 1997;90:535-543.
7. Ross AM, Gao R, Coyne KS, Chen J, Yao K, Yang Y, et al; TUCC Investigators. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J. 2001;142:244-247.
8. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
9. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
10. Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke. 2011;6:523-530.
11. Chen CH, Hsieh CY, Lai TB, Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose. J Thromb Haemost. 2012;10:1270-1275.
12. Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.
13. Hu HH, Teng MM, Hsu LC, Wong WJ, Wang LM, Luk YO, et al. A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window. Stroke. 2006;37:918-919.
14. Chao AC, Teng MM, Chung CP, Weng HY, Chen YY, Yang FY, et al. Preliminary efficacy report of a novel thrombolytic agent for acute ischaemic stroke within a 5-hour window. CNS Drugs. 2007;21:937-946.
15. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909.
16. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
17. Kufner A, Nolte CH, Galinovic I, Brunecker P, Kufner GM, Endres M, et al. Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke. Stroke. 2013;44:407-413.
18. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176.
19. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006;66:165-171.
20. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderateintensity anticoagulation? Br J Clin Pharmacol. 2005;59:582-587.
21. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817-821.
22. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891-1896.
23. Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). http://clinicaltrials.gov/ct2/show/NCT01422616. Accessed July 3, 2013.
24. Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, et al; Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. 2011;123:739-749.
25. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309:2480-2488.